2005
DOI: 10.1038/sj.bjc.6602748
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: The aim of this study was to compare the irinotecan/cisplatin regimen with cisplatin as second-line chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC) pretreated with a taxane/gemcitabine regimen. Patients (n ¼ 147) with stage IV NSCLC pretreated with a taxane/gemcitabine regimen were randomly assigned to receive either irinotecan (110 mg m À2 , day 1 and 100 mg m À2 , day 8) and cisplatin (80 mg m À2 , day 8) (IC; n ¼ 74) or CDDP (80 mg m À2 , day 1) (C; n ¼ 73) every 3 weeks. Patients … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
16
0
1

Year Published

2006
2006
2022
2022

Publication Types

Select...
8
2

Relationship

0
10

Authors

Journals

citations
Cited by 39 publications
(18 citation statements)
references
References 36 publications
(45 reference statements)
1
16
0
1
Order By: Relevance
“…The results of our study are strengthened by the findings of other five randomized clinical trials, that compared a doublet chemotherapy with a single chemotherapeutic agent as second line therapy of patients affected by NSCLC [28][29][30][31][32]. Namely, three trials compared 3-weekly docetaxel with a combination of docetaxel and gemcitabine [28] or docetaxel and irinotecan [29,30].…”
Section: Discussionsupporting
confidence: 72%
“…The results of our study are strengthened by the findings of other five randomized clinical trials, that compared a doublet chemotherapy with a single chemotherapeutic agent as second line therapy of patients affected by NSCLC [28][29][30][31][32]. Namely, three trials compared 3-weekly docetaxel with a combination of docetaxel and gemcitabine [28] or docetaxel and irinotecan [29,30].…”
Section: Discussionsupporting
confidence: 72%
“…Thirteen phase II studies [19][20][21][22][23][24][25][26][27][28][29][30][31] regarding irinotecancontaining second-line chemotherapy for patients with NCSLC were found, and they are summarized in Table 3. Among them, three studies employed regimens consisting of irinotecan and cisplatin (the top three lines of Table 3), and reported promising response rates and survival data similarly to ours.…”
Section: Discussionmentioning
confidence: 99%
“…Several randomized trials compared a two-drug combination chemotherapy versus single-agent treatment [69][70][71][72][73][74][75]. An individual patient data meta-analysis pooled together the data of 6 of those trials [76]: combination chemotherapy produced a significant increase in objective response rate, a modest prolongation in progression-free survival, without significant differences in overall survival.…”
Section: Recommendationsmentioning
confidence: 99%